The Jesse Z. and Lea Shafer, Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, 14 Kaplan St., 49202, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Endocrinol Invest. 2018 Aug;41(8):969-975. doi: 10.1007/s40618-017-0823-7. Epub 2018 Jan 5.
Obesity, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA) are associated with chronic low-grade inflammation. Iron metabolism is linked with insulin-resistant states and with OSA in adults. The association of body iron status with T2DM in children remains undefined. We aimed to evaluate plasma interleukin-6 (IL-6), hepcidin, and soluble transferrin receptor (sTfR) levels in obese patients with T2DM or impaired glucose tolerance (IGT) and in those without, and the contribution of OSA to their levels.
In this cross-sectional study, obese children and adolescents with and without T2DM/IGT underwent overnight polysomnography. Fasting plasma concentrations of IL-6, hepcidin, and sTfR were measured and evaluated according to glycemic status (T2DM/IGT and normal glucose tolerance) and the presence of OSA.
Ten patients with T2DM (age 15.9 ± 3.6 years), 8 with IGT (age 13.1 ± 2.5 years) and 20 subjects with normal glucose tolerance matched for body mass index standard deviation score (age 12.6 ± 3.3 years) were studied. Sleep measures or IL-6, hepcidin, and sTfR levels were not significantly different between the group with T2DM/IGT vs. the control group. No significant differences were found in hepcidin or sTfR levels between patients with OSA and those without. However, patients with OSA showed higher plasma IL-6 values compared with those without (4.56 ± 2.92 vs. 2.83 ± 1.54 pg/ml, P = 0.025), and the highest values were evident in patients affected by both T2DM/IGT and OSA.
Higher IL-6 levels were associated with both glycemic status and OSA. No differences in body iron regulator levels were found in obese patients with T2DM/IGT compared to those without or in those with OSA compared to those without. Further longitudinal studies in larger population samples are warranted.
肥胖、2 型糖尿病(T2DM)和阻塞性睡眠呼吸暂停(OSA)与慢性低度炎症有关。铁代谢与胰岛素抵抗状态和成人 OSA 有关。儿童铁状态与 T2DM 的关系尚不清楚。我们旨在评估肥胖伴 T2DM 或糖耐量受损(IGT)及不伴 T2DM/IGT 的患者的血浆白细胞介素-6(IL-6)、铁调素和可溶性转铁蛋白受体(sTfR)水平,并评估 OSA 对其水平的影响。
在这项横断面研究中,患有 T2DM/IGT 及不伴 T2DM/IGT 的肥胖儿童和青少年接受了整夜多导睡眠图检查。测量空腹血浆 IL-6、铁调素和 sTfR 浓度,并根据血糖状态(T2DM/IGT 和正常糖耐量)和 OSA 的存在情况进行评估。
研究了 10 例 T2DM 患者(年龄 15.9 ± 3.6 岁)、8 例 IGT 患者(年龄 13.1 ± 2.5 岁)和 20 例 BMI 标准差评分匹配的正常糖耐量受试者(年龄 12.6 ± 3.3 岁)。T2DM/IGT 组与对照组之间的睡眠测量值或 IL-6、铁调素和 sTfR 水平无显著差异。OSA 患者与无 OSA 患者之间的铁调素或 sTfR 水平无显著差异。然而,OSA 患者的血浆 IL-6 值高于无 OSA 患者(4.56 ± 2.92 与 2.83 ± 1.54 pg/ml,P = 0.025),且 T2DM/IGT 合并 OSA 的患者 IL-6 值最高。
较高的 IL-6 水平与血糖状态和 OSA 均有关。与不伴 T2DM/IGT 的肥胖患者或不伴 OSA 的肥胖患者相比,T2DM/IGT 肥胖患者的铁调节因子水平无差异。需要在更大的人群样本中进行进一步的纵向研究。